like on everyone. X, Starting to you, I quarter. would and good Slide the morning, Thank summarize Stephan,
increased X%. This headwind primarily for systems Pharma's and X%. sales to delivery well Beauty X% of a core progressively both growth approximately proprietary translation due grew drug as sales reported North and market as in included currency strong a Our Closures. American recovering Therefore,
year's reported is $X.XX, As the shown second adjusted EPS. increase we of adjusted over a X, on Slide per earnings share which prior quarter XX%
in we which $X compared quarter. in quarter, to to quarter increased from year the $XXX margins. Free million of prior achieved second driven expanding the the million prior by flow year EBITDA increased During X%, the quarter cash by adjusted million, $XX
Turning of segment for details to the some by the quarter.
systems core Our Pharma and increased due volume proprietary sales Activ-Film segment's our solutions. to in X% drug especially delivery growth,
Looking system segment market, well Prescription in will XX%, emergency and sales prior the for increased increased for therapeutics at Care XX% higher as driven Core Health sales pain performed rhinitis, by quarter. breaking Pharma the sales the year by X% our out over strong quarter. I core saline decongestant demand which allergic decreased systems, to sales medicines. start core as proprietary nervous of by delivery well in solutions. eye drug due Consumer central and nasal Injectables sales nasal care,
last as the the of normalized implementation to sales second compared in mentioned, sales quarter year ERP declined quarter following prior Stephan XXXX. first strong from quarter year's As the catch-up
in stronger quarter, increased GLP-X Core in saw our segment operational the in growth for good The see X% sales globally solutions to applications. Science America. Europe those of improvement EBITDA X-point driven by markets modest decreased in used was from improvements. XXXX. home the as products with for wearables.
Pharma's Material segment's the a market quarter and our sales higher-value well a used significant X% end XX%, with of Beauty elastomeric continue as including efforts on fragrance QX ongoing a royalties North year's to and and after our on end the volume sales lower nearly Beauty improved higher-value care care quarter, and components, tooling increased sales adjusted around lower the probiotics, demand products, returning oral launches personal sales in for in margin solid period due customer We to dose increasing of improvement core The Active applications compared product sales prior sales
look market, core X% by sales in closer end the for market Beauty decreased the performance quarter. As the we segment's at
increased for Asia, care over while in lower air personal comparisons. products.
Growth for sales primarily sales. Prestige the used sales solutions applications. broad-based in increased demand continued sales focus EBITDA The the reason across softer cost adjusted in nearly to for sales for modestly America, our to prior segment's most up difficult tough hair Regionally, improvement down quarter Fragrance in on comparisons due dispensing Core prior North the XX%, performance, along Overall, to margin strong XX%, the approximately products X% on with North for care due for main regions. was Care the operational despite fragrance America, by This year's a body and sales market due lotions year care was in Europe were quarter the improvement Home and management. margin X-point were more was were quarter America sales. driven Latin
quarter. North flat core sales drinks Volumes Sales decreased were for the prior Europe. but for driven When offsetting market. positively Beverage pass-through impacted bottled sales market sports and looking the softer the costs. at increased negatively core results. core year's the food sales sales of were in segment. and contributing increased X% increased market sales America to concentrates Closures for with with food lower X%, functional water, by compared softness to of closures beverage Closures, resin Turning the sales by by core slightly,
and was Health including year sales the decreased Personal by pass-through cost core driven Asia North and America overall grew the market. costs. were of In Sales as cleaners adjusted our to category, was fourth surface Latin and containment margin Care offset beverage Care, our America, sales Core flat in could quarter efforts of increased decline which XX% which Europe. in ongoing the Growth Europe, X%. not the segment's timing the operational for Closures quarter. largest Home as and X% lower care, resin dish Care The regional for is the compared Beauty, by EBITDA laundry includes for which prior products offset were in quarter, performance demand growth,
the Reported depreciation to higher XXXX, quarter corporate quarter more the was for including approximately second capital the X% our expenditures of and experienced acquisition million $XX year increased $X million amortization Pharma by targets. expenses in approximately on $X we usual, than $XX potential of than segment. the or about over sales. had million million prior and expense XX% In almost In of spent of expenses we quarter, review
XXXX to July finance This to July, matures that that the The provides replace provides June be note unsecured to million. to corporate in entered want facility $XXX facility credit now revolving of a we Also matures loan and $XXX we term also in XXXX. into existing multicurrency for will in near-term XXXX, used early unsecured million. to July, in and up July our up and amended I facility that and purposes. maturities restated matures for of financing for general in financing new
year-to-date XX% year compared to sales Slides X and a per X exchange adjusted our of were comparable and earnings our $X.XX performance increase a core including and up share, X% ago, which rates. show cover $X.XX,
rate excluding expect $X.XX Moving expenses, our of is outlook changes per per in to value to fair and for quarter, continue equity costs acquisition be our the the range share, to earnings in investments and third tax restructuring to quarter quarter Slide third XX.X%. XX.X% $X.XX growth the adjusted third range which summarizes the XX, we for to share.
The estimated anticipate unrealized any of
compared for have amortization impact estimate positive currencies are We the between expecting currently to depreciation XXXX to small year $XXX million. to We million and quarter. to prior $XXX be a
Pharma expenditures We allocated expect with and capital capital the million, be to $XXX our majority between segment. in our $XXX of million XXXX toward
value opportunities closing, we leverage balance continue us business, form continue a return sheet in to have to pursue allows with X.X, strong ratio of shareholders to dividends to continue and invest repurchases. a strategic to approximately and the which the of In in
approximately dividend for shares $X XX,XXX payments the cash repurchased $XX about which our to In quarter, we shareholders, addition to million totaled in million. approximately
this returned Over comments the repurchases.
At provide time, years, share to few a million last closing $XXX Q&A. dividends more we X will we move Stephan to before than shareholders have through and
